Starts & Stops: Medtronic's Symplicity Flatlines For Heart Failure
Starts & Stops is a regular feature highlighting Medtech Insight editors' picks of noteworthy medtech clinical trial initiations, completions and suspensions over the last month. This edition, which looks at trial updates from Sept. 8 through to Oct. 7, throws the spotlight on four studies that had the plug pulled, including Medtronic's Symplicity-HF trial.
You may also be interested in...
Starts & Stops is a regular feature highlighting Medtech Insight editors' picks of noteworthy medtech clinical trial initiations, completions and suspensions each month. This month's edition includes seven trial-terminations – not as many as last month, but more than usual – for a variety of reasons, including Boston Scientific's suspension of all its trials of the Lotus transcatheter aortic valve due to a manufacturing problem.
Could the “next big thing” in medtech already be set for the scrap heap? Medtronic has just reported that the US pivotal trial of its Symplicity renal denervation device has not met its primary efficacy endpoint, scuppering its chances of FDA approval and sending the firm’s stock down 5% in morning trading.
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.